Search for this and you will get a confident “yes” from some sources and a careful “not exactly” from others. Both are defensible, and the gap between them is genuinely informative — it explains why ulcerative colitis is treated the way it is.
The distinction in one paragraph
A classical autoimmune disease has an identified target in your own tissue and antibodies that attack it. Type 1 diabetes has antibodies against pancreatic islet cells. Hashimoto’s thyroiditis has antibodies against thyroid peroxidase. You can measure the antibody, name the tissue, and show the mechanism.
An immune-mediated inflammatory disease has your immune system doing the damage without a single identified self-target. Ulcerative colitis sits here, alongside Crohn’s disease, psoriasis, rheumatoid arthritis and ankylosing spondylitis.
The damage is just as real, and it is just as much your own immune system. What is missing is the clean “antibody against X” story.
What the immune system is reacting to
The current model is that the immune response in ulcerative colitis is aimed at normal gut bacteria, not at colon tissue.
Your colon holds trillions of bacteria. In most people, the immune system tolerates them — which is a remarkable achievement, given it is separated from them by a single layer of cells and a coat of mucus. That tolerance is actively maintained, and it depends on both the barrier holding and the immune system reading the bacteria correctly.
In ulcerative colitis, both parts appear to be compromised:
- Barrier function. Genetic variants affecting the mucus layer and the tight junctions between epithelial cells allow more bacterial contact with immune tissue than there should be.
- Bacterial recognition. Variants in the pathways that sense bacterial components lead to an inflammatory response where there should be tolerance.
Once that response establishes itself in the rectal lining, it becomes self-sustaining: inflammation damages the barrier, the damaged barrier admits more bacterial contact, which drives more inflammation. This is why the disease runs continuously upwards from the rectum rather than appearing in random patches, and why it affects the innermost lining — that is where the interface is.
The genetics
Genome-wide studies have linked over 200 genetic loci to inflammatory bowel disease. No single one causes it; each shifts the odds slightly, and the combination creates susceptibility.
What those loci have in common is telling. They cluster around:
- Innate recognition of bacterial components.
- Epithelial barrier integrity and mucus production.
- Regulatory T cell function — the brake pedal on immune responses.
- Autophagy, the cellular housekeeping process that clears intracellular bacteria.
That is not a list you would expect from a disease attacking its own tissue. It is a list from a disease about managing bacteria.
Inheritance is real but not deterministic: around one in six people with ulcerative colitis has a close relative with IBD, and identical twin concordance is roughly 15 per cent — high enough to prove genes matter, low enough to prove they are not the whole story.
The antibodies that nearly worked
Two antibodies turn up in this conversation.
pANCA is found more often in ulcerative colitis. ASCA is found more often in Crohn’s. For a while there was real hope these could tell the two diseases apart from a blood sample.
They cannot — not reliably enough. Neither is sensitive or specific enough to diagnose either disease or to exclude it, and NICE does not recommend them for diagnosis. Colonoscopy with biopsies remains the test, because the microscopic pattern of inflammation is what actually distinguishes the two.
The absence of a dependable autoantibody is precisely why “autoimmune” is the slightly wrong word.
Why any of this affects treatment
If a disease had one antibody against one target, you would block that antibody. Ulcerative colitis treatment instead works by damping down inflammatory pathways at various points:
- Aminosalicylates act locally on the bowel lining. First line for mild to moderate disease, and the mainstay of maintenance.
- Corticosteroids suppress inflammation broadly and quickly. For flares, not for staying on.
- Immunosuppressants such as azathioprine reduce immune cell proliferation.
- Biologics including anti-TNF drugs like infliximab, and anti-integrin and anti-interleukin agents, block specific inflammatory signals.
- JAK inhibitors such as tofacitinib interrupt intracellular signalling downstream of several of those signals at once.
Every one of these is a brake on an immune response. None is an antidote to an antibody. That is the practical consequence of the distinction.
It is also why the microbiome keeps appearing in colitis research — if the immune system is reacting to bacteria, changing the bacteria is a logical place to intervene. Faecal microbiota transplantation has been trialled in ulcerative colitis with some genuinely positive results, but it is not yet an established NHS treatment and should not be attempted outside a trial.
The conditions that travel with it
Because this is an immune-mediated disease, other immune-mediated conditions occur more often alongside it. Most people get none, but it is worth knowing the list:
- Primary sclerosing cholangitis — inflammation of the bile ducts. The most important one, because it substantially raises bowel cancer risk and means annual surveillance colonoscopy rather than the usual intervals.
- Inflammatory arthritis, including of the spine and sacroiliac joints.
- Uveitis and episcleritis — eye inflammation. Sudden eye pain or visual change needs same-day assessment.
- Erythema nodosum and pyoderma gangrenosum — skin conditions that often track disease activity.
If you develop joint pain, eye symptoms or an unusual skin lesion, mention the colitis. These connections are frequently missed because people present to different specialties.
So what should you say?
If someone asks, “autoimmune” is fine. It conveys the thing that matters: this is your immune system, it is not an infection, and it will not clear on its own.
If you want to be exact, it is an immune-mediated inflammatory disease. And the reason for the pedantry is useful — the immune system here is not confused about which tissue is yours. It is confused about which bacteria are a threat.
